Frontlight ResearchEarly access
TerminatedPhase 4
Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
Key facts
- Who runs it
- I.R.C.C.S. Fondazione Santa Lucia
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 30 people enrolled
- Started
- 31 Jan 2023
- Ended
- 11 Apr 2024
- Type of study
- Interventional
- Treatments tested
- Ozanimod Oral Capsule
- Record updated
- 15 January 2025
- Why it stopped
- Sponsor's decision
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- 1) Diagnosis of MS accordingly to 2017 revised McDonald criteria; 2) Patients candidate to receive Ozanimod therapy (disease characteristics, EDSS, age, lifestyle, disease progression, etc.); 3) Age between 18 and 45 years; 4) EDSS score from 0 to 4; 5) Signature and date of written ICF prior to entering the study
Who cannot take part
- The presence of any of the following will exclude a patient from study enrolment:; Ongoing immunomodulatory or immunosuppressive treatment; Other autoimmune comorbidities (i.e. antiphospolipid syndrome); Treatment with steroids in the last 30 days before enrollment; Acute inflammatory status not MS related (i.e. bacterial or viral infections) in the previous 30 days; Patients unable to read and understand the documents of the study; Participation in any interventional clinical trials or compassionate use programs; Contraindications and "not-recommendations" reported in SmP
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective interventional study with a 12-month follow-up of patients diagnosed with Multiple Sclerosis. Enrollment includes patients for whom Ozanimod will be prescribed based on regular clinical practice. It is proposed to integrate the measurements obtained using multiple instruments, with the aim of analyzing the immunological landscape, connectivity networks and anatomical traits of neurodegeneration.
Read full original descriptionShow less
Patients will return for imaging and noninvasive electrophysiological studies 3, 6, and 12 months after initiation of therapy. On the same day, blood samples will be taken and immunological and biochemical tests will be performed.
The group in the trial
- PatientTreatment being tested
Treatment: Ozanimod Oral Capsule
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multidimensional Integrated Assessment of Neurological and Immunological Patterns to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
- Record updated
- 15 January 2025